Most Read Articles
Elvira Manzano, 4 days ago
Bisphosphonates have proven antifracture efficacy and remain to be the cornerstone of osteoporosis treatment. However, a drug holiday is of particular importance with bisphosphonates due to some signals with long-term use of the drug, including rare incidence of atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ), says a leading endocrinologist at AFOS 2017.
Yesterday
Breast cancer patients have notably different microbiomes in the local breast tissue and urinary tract, a recent study reveals. Particularly, species in the Methylobacterium genus are reduced in the local breast tissue while the urinary tract is enriched in gram-positive bacteria.
Pearl Toh, 13 Oct 2017
Women with higher plasma tryptophan concentrations were less likely to have poor sleep quality during pregnancy, especially among those with anxiety symptoms, according to the GUSTO* study.
Tristan Manalac, Yesterday
Statin use, particularly in smokers, obese patients and nondiabetics, has a strong and dose-dependent association with decreasing risk of pancreatic ductal adenocarcinoma (PDAC), according to a new study.

SGLT-2 inhibitors may lower heart failure, death rates in T2D patients regardless of CVD status

Audrey Abella
16 Jun 2017

Sodium-glucose transporter-2 inhibitors (SGLT-2i) were associated with a significant reduction in the rates of death and hospitalization due to heart failure (HF) in patients with type 2 diabetes (T2D) regardless of pre-existing cardiovascular disease (CVD), according to a new analysis of the CVD-REAL* study presented at the American Diabetes Association’s 77th Scientific Sessions held in San Diego, California, US.

“The benefits seen with [SGLT-2i] are likely to be a class effect,” said Dr Matthew Cavender from the University of North Carolina School of Medicine, Chapel Hill, North Carolina, US, as the association remained consistent despite the geographic variations relative to the specific SGLT-2i used and the lack of heterogeneity across participating countries.

In this multinational (US, UK, Norway, Sweden, and Denmark) study, researchers evaluated 306,156 participants with T2D who had undergone SGLT-2i treatment. Of these, 13 percent (n=39,293) had established CVD, and 950 new HF events were reported. HF and death rates in patients with and without prior CVD history were compared against HF rates in new users of SGLT-2i and other glucose-lowering drugs (oGLD).

Compared with oGLD, SGLT-2i was associated with decreased HF rates in patients with and without prior CVD (hazard ratio [HR], 0.69, 95 percent confidence interval [CI], 0.59–0.80 and HR, 0.45, 95 percent CI, 0.32–0.63, respectively). [ADA 2017, abstract 377-OR]

Similar results were observed for death with and without existing CVD (HR, 0.47, 95 percent CI, 0.36–0.61 and HR, 0.54, 95 percent CI, 0.44–0.66, respectively) with SGLT-2i vs oGLD use.

SGLT-2i use also resulted in decreased rates of death due to HF with and without existing CVD (HR, 0.59, 95 percent CI, 0.52–0.67 and HR, 0.52, 95 percent CI, 0.44–0.61, respectively) vs oGLD use.

The findings suggest that the incidence of HF in diabetic patients could be reduced with SGLT-2i use, said Cavender. “[Our] results go one step further to show that SGLT-2 inhibition may benefit all patients with diabetes, regardless of whether they have known [CVD].”

These findings were consistent with the full results of the CVD-REAL study, which showed a reduced risk of death (HR, 0.49; p<0.001) and hospitalization for HF (HR, 0.61; p<0.001) with SGLT-2i vs oGLD. [Circulation 2017;doi:10.1161/CIRCULATIONAHA.117.029190]

However, as SGLT-2i is a relatively new class, longer follow-ups are warranted to evaluate its effects over time, noted the researchers.

Overall, this study has important clinical implications and underlines the need for new treatment alternatives for T2D since it is a major CVD risk factor. [Lancet 2010;375:2215-2222; Circulation 2008;117:2544-2565] Together with other ongoing randomized trials, the findings provide further evidence regarding the potential role of SGLT-2i in T2D management, said Cavender. “[These data may] help establish the real-world effectiveness of treatments in a broad population of patients from clinical practice.”

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Elvira Manzano, 4 days ago
Bisphosphonates have proven antifracture efficacy and remain to be the cornerstone of osteoporosis treatment. However, a drug holiday is of particular importance with bisphosphonates due to some signals with long-term use of the drug, including rare incidence of atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ), says a leading endocrinologist at AFOS 2017.
Yesterday
Breast cancer patients have notably different microbiomes in the local breast tissue and urinary tract, a recent study reveals. Particularly, species in the Methylobacterium genus are reduced in the local breast tissue while the urinary tract is enriched in gram-positive bacteria.
Pearl Toh, 13 Oct 2017
Women with higher plasma tryptophan concentrations were less likely to have poor sleep quality during pregnancy, especially among those with anxiety symptoms, according to the GUSTO* study.
Tristan Manalac, Yesterday
Statin use, particularly in smokers, obese patients and nondiabetics, has a strong and dose-dependent association with decreasing risk of pancreatic ductal adenocarcinoma (PDAC), according to a new study.